<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293589</url>
  </required_header>
  <id_info>
    <org_study_id>00042158</org_study_id>
    <nct_id>NCT03293589</nct_id>
  </id_info>
  <brief_title>Open Versus Endovascular Revascularization in Patients With End-stage Renal Disease</brief_title>
  <acronym>OERESRD</acronym>
  <official_title>Open Versus Endovascular Revascularization of Below-knee Arteries in Patients With End-stage Renal Disease and Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with end-stage renal disease and critical limb ischemia still poses
      challenges to vascular medicine due to limited survival, comorbidities and infrapopliteal
      involvement of arteriosclerosis in these patients.

      Most optimal vascular therapy mode has not been finally decided in these patients.

      Therefore retrospective analysis of patients receiving open surgical and endovascular
      revascularisation was performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Query of internal clinical database for identification of patients (2009-2017)with end-stage
      renal disease and critical limb ischemia, receiving either open surgical (Group I &quot;OR&quot;) or
      endovascular revascularisation (Group II &quot;EVT&quot;).

      Furthermore, retrospective comparison as to morphological criteria (lesion length, peripheral
      run-off, plantar arch) and comorbidities.

      Prospective follow-up of identified patients by means of telephone contacts and/or clinical
      examination of evaluation of Long-term outcome measures (Overall survival, Amputation-free
      survival, wound healing)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Actual">September 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amputation free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of limb salvage and survival as Composite endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of Overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Amputation</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of Major Amputation rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">77</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>OR</arm_group_label>
    <description>patients treated with open revascularization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVT</arm_group_label>
    <description>patients treated with endovascular revascularization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open revascularization</intervention_name>
    <description>surgical revascularization (i.e. Bypass surgery)</description>
    <arm_group_label>OR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular revascularization</intervention_name>
    <description>endovascular revascularization (stent, ballon angioplasty)</description>
    <arm_group_label>EVT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        study Population comprises of all dialysis patients treated for critical limb ischemia by
        means of surgical or endiovascular Intervention at University Hospital Erlangen between
        2009 and 2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of end-stage renal disease

          -  presence of critical limb ischemia (Ankle-brachial-index &gt; 0.4 or presence of rest
             pain or ischemic ulcers or gangrene)

          -  revascularisation by means of Bypass or endovascular therapy

        Exclusion Criteria:

          -  conservative Treatment

          -  non-atherosclerotic lesions

          -  coagulation disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen, Department of Vascular Sugery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Meyer, MD</last_name>
    <phone>0049 9131 85 32968</phone>
    <email>alexander.meyer@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Meyer, MD</last_name>
      <phone>0049 09131 85 32968</phone>
      <email>alexander.meyer@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>Alexander Meyer, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>end-stage renal disease</keyword>
  <keyword>critical limb ischemia</keyword>
  <keyword>surgical revascularisation</keyword>
  <keyword>endovascular therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

